now trading at 28 cps, page-35

kakoli, Thanks for that Interesting data. The good thing about PRR is that each product milestone completed so far has been positive. The other big risk is always the financial position. The $21mill picked up in the placement has markedly de-risked Prima and the spp should ensure that funding is there to complete all trials. An enviable position for a bio-tech imo. In major market downturns, the stocks that usually get hammered the most are those that are debt and debt covenant burdened. PRR has no debt and has plenty of cash so it is a safer bet than a lot of other stocks.